Latest News and Press Releases

– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3 Study to Demonstrate...

Agios announced new data on mitapivat and tebapivat (AG-946) will be featured in oral and poster presentations during the ASH Annual Meeting.

Agios reports business highlights and financial results for the third quarter, ended September 30, 2024.

Agios today announced that enrollment is complete for the Phase 3 RISE UP study in sickle cell disease patients.

CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...

Agios today announced that the FDA has granted orphan drug designation to tebapivat (AG-946) for the treatment of myelodysplastic syndromes (MDS).

Agios is scheduled to present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 a.m. ET.

Agios will receive a total of $1.1 billion in milestone payments following the FDA approval of vorasidenib

– Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 – – Announced $905...

– ACTIVATE-KidsT is Agios’ First Pediatric Data Readout;Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adultswith PK Deficiency Who are Regularly Transfused – –...